drugset / Trial / NCT00291447

111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen

NCT00291447 ↗

Phase 1 Completed 8 enrolled Ludwig Institute for Cancer Research
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this clinical trial is to describe the toxicity, biodistribution, pharmacokinetics and tumour uptake of a single infusion of ch806 (tagged with a trace amount of radioactive 111-Indium: 111In-ch806) in patients with advanced tumours expressing the 806 antigen.

Timeline

Start
2005-05
Primary completion
2006-02-16
Completion
2006-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ch806 Monoclonal antibody 5 mg/m2 Intravenous
Subject ch806 Monoclonal antibody 10 mg/m2 Intravenous
Subject ch806 Monoclonal antibody 20 mg/m2 Intravenous
Subject ch806 Monoclonal antibody 40 mg/m2 Intravenous

Indications